AI Engines For more Details: Perplexity Kagi Labs You
Pruritus: Metixene hydrochloride is commonly prescribed to relieve itching associated with various dermatological conditions such as eczema, allergic reactions, insect bites, and other skin irritations. It exerts its antipruritic effects by blocking the action of acetylcholine, a neurotransmitter involved in itch sensation.
Nausea and Vomiting: Metixene hydrochloride is sometimes used as an antiemetic agent to prevent or alleviate nausea and vomiting associated with motion sickness, chemotherapy, anesthesia, and other conditions. It works by blocking muscarinic receptors in the vomiting center of the brain and in the gastrointestinal tract, thereby reducing the sensation of nausea and the urge to vomit.
Vertigo: Metixene hydrochloride may also be prescribed to alleviate symptoms of vertigo and dizziness, particularly in cases where these symptoms are related to inner ear disturbances or vestibular disorders. Its anticholinergic properties help to stabilize inner ear function and reduce the sensation of dizziness.
Allergic Rhinitis: In some cases, metixene hydrochloride may be used to manage symptoms of allergic rhinitis (hay fever) such as sneezing, itching, and runny nose. It can help alleviate these symptoms by blocking the action of acetylcholine in the nasal passages and reducing the release of histamine and other inflammatory mediators.
Parkinson's Disease: Metixene hydrochloride has been used as an adjunctive treatment in Parkinson's disease to help alleviate tremors, rigidity, and other motor symptoms. However, its use in Parkinson's disease is less common today due to the availability of more effective medications with fewer side effects.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Parabacteroides distasonis | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Akkermansiaceae | family | Decreases |
| 0 | 1 | Roseburia | genus | Decreases |
| 0 | 1 | Parabacteroides | genus | Decreases |
| 1 | 0 | Akkermansia | genus | Decreases |
| 0 | 1 | Ruminococcus | genus | Decreases |
| 0 | 1 | Agathobacter | genus | Decreases |
| 0 | 1 | Bacteroides | genus | Decreases |
| 0 | 1 | Coprococcus | genus | Decreases |
| 0 | 1 | Eggerthella | genus | Decreases |
| 0 | 1 | Lachnospira | genus | Decreases |
| 0 | 1 | Mediterraneibacter | genus | Decreases |
| 0 | 1 | Odoribacter | genus | Decreases |
| 0 | 1 | Phocaeicola | genus | Decreases |
| 0 | 1 | Clostridium | genus | Decreases |
| 0 | 1 | Segatella | genus | Decreases |
| 0 | 1 | Enterocloster | genus | Decreases |
| 0 | 1 | Blautia | genus | Decreases |
| 0 | 1 | Clostridium perfringens A | no rank | Decreases |
| 0 | 1 | Clostridium perfringens C | no rank | Decreases |
| 0 | 1 | Clostridium perfringens CPE | no rank | Decreases |
| 0 | 1 | environmental samples | no rank | Decreases |
| 0 | 1 | unclassified Akkermansia | no rank | Decreases |
| 0 | 1 | Clostridium perfringens D | no rank | Decreases |
| 0 | 1 | Clostridium perfringens B | no rank | Decreases |
| 0 | 1 | Clostridium perfringens E | no rank | Decreases |
| 1 | 0 | Clostridium perfringens | species | Decreases |
| 1 | 0 | Agathobacter rectalis | species | Decreases |
| 1 | 0 | Akkermansia muciniphila | species | Decreases |
| 1 | 0 | Bacteroides caccae | species | Decreases |
| 1 | 0 | Bacteroides fragilis | species | Decreases |
| 1 | 0 | Bacteroides ovatus | species | Decreases |
| 1 | 0 | Bacteroides thetaiotaomicron | species | Decreases |
| 1 | 0 | Bacteroides uniformis | species | Decreases |
| 1 | 0 | Bacteroides xylanisolvens | species | Decreases |
| 1 | 0 | Coprococcus comes | species | Decreases |
| 1 | 0 | Lachnospira eligens | species | Decreases |
| 1 | 0 | Odoribacter splanchnicus | species | Decreases |
| 1 | 0 | Parabacteroides distasonis | species | Decreases |
| 1 | 0 | Parabacteroides merdae | species | Decreases |
| 1 | 0 | Phocaeicola vulgatus | species | Decreases |
| 1 | 0 | Segatella copri | species | Decreases |
| 1 | 0 | Mediterraneibacter gnavus | species | Decreases |
| 1 | 0 | Enterocloster bolteae | species | Decreases |
| 1 | 0 | Ruminococcus bromii | species | Decreases |
| 0 | 1 | Akkermansia massiliensis | species | Decreases |
| 0 | 1 | Candidatus Akkermansia intestinavium | species | Decreases |
| 1 | 0 | Blautia obeum | species | Decreases |
| 1 | 0 | Roseburia intestinalis | species | Decreases |
| 1 | 0 | Eggerthella lenta | species | Decreases |
| 0 | 1 | Akkermansia glycaniphila | species | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.6 | 0.6 | |
| Acne | 0.6 | 0.6 | |
| ADHD | 3.1 | 0.6 | 4.17 |
| Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.4 | 0.25 |
| Allergic Rhinitis (Hay Fever) | 1.5 | 0.4 | 2.75 |
| Allergies | 3 | 2.7 | 0.11 |
| Allergy to milk products | 1.7 | 0.7 | 1.43 |
| Alopecia (Hair Loss) | 0.7 | 0.7 | |
| Alzheimer's disease | 4.7 | 4.5 | 0.04 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2.8 | 0.9 | 2.11 |
| Ankylosing spondylitis | 2.3 | 1.4 | 0.64 |
| Anorexia Nervosa | 1.1 | 2.9 | -1.64 |
| Antiphospholipid syndrome (APS) | 0.7 | 0.7 | |
| Asthma | 2.4 | 1.8 | 0.33 |
| Atherosclerosis | 1.2 | 2.5 | -1.08 |
| Atrial fibrillation | 2.6 | 1.9 | 0.37 |
| Autism | 7.4 | 7.4 | 0 |
| Autoimmune Disease | 0.7 | -0.7 | |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Biofilm | 0.5 | 0.5 | |
| Bipolar Disorder | 1.5 | 1.4 | 0.07 |
| Brain Trauma | 1.1 | -1.1 | |
| Breast Cancer | 0.3 | 0.3 | 0 |
| Cancer (General) | 0.3 | 1.3 | -3.33 |
| Carcinoma | 1.7 | 1.4 | 0.21 |
| Celiac Disease | 1.9 | 2.1 | -0.11 |
| Cerebral Palsy | 0.9 | 1.3 | -0.44 |
| Chronic Fatigue Syndrome | 3.7 | 4.7 | -0.27 |
| Chronic Kidney Disease | 2.1 | 2.1 | 0 |
| Chronic Lyme | 0.8 | -0.8 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.3 | 1.1 | -2.67 |
| Chronic Urticaria (Hives) | 0.2 | 1.8 | -8 |
| Coagulation / Micro clot triggering bacteria | 0.4 | 1 | -1.5 |
| Cognitive Function | 1.8 | 1 | 0.8 |
| Colorectal Cancer | 5.6 | 1.6 | 2.5 |
| Constipation | 1.5 | 0.7 | 1.14 |
| Coronary artery disease | 1.1 | 2.7 | -1.45 |
| COVID-19 | 5.8 | 9.6 | -0.66 |
| Crohn's Disease | 6 | 5.4 | 0.11 |
| Cushing's Syndrome (hypercortisolism) | 0.9 | -0.9 | |
| cystic fibrosis | 1 | -1 | |
| deep vein thrombosis | 2.3 | 1.1 | 1.09 |
| Depression | 7.6 | 6.3 | 0.21 |
| Eczema | 0.7 | 0.8 | -0.14 |
| Endometriosis | 1.1 | 1.7 | -0.55 |
| Epilepsy | 2.1 | 2.5 | -0.19 |
| erectile dysfunction | 1 | 1 | |
| Fibromyalgia | 2.2 | 2.3 | -0.05 |
| Functional constipation / chronic idiopathic constipation | 4 | 4 | 0 |
| gallstone disease (gsd) | 2.1 | 0.9 | 1.33 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.2 | 0.5 | 1.4 |
| Generalized anxiety disorder | 1.9 | 1.7 | 0.12 |
| giant cell arteritis | 0.2 | -0.2 | |
| Gout | 2.2 | 1.2 | 0.83 |
| Graves' disease | 1 | 1.6 | -0.6 |
| Gulf War Syndrome | 0.6 | 2.2 | -2.67 |
| Halitosis | 0.3 | 0.3 | |
| Hashimoto's thyroiditis | 2.3 | 1 | 1.3 |
| Heart Failure | 2.6 | 2 | 0.3 |
| hemorrhagic stroke | 0.4 | 0.4 | |
| Hidradenitis Suppurativa | 0.6 | 0.6 | |
| High Histamine/low DAO | 1.4 | 0.3 | 3.67 |
| hypercholesterolemia (High Cholesterol) | 0.5 | 0.6 | -0.2 |
| hyperglycemia | 0.6 | 1.9 | -2.17 |
| Hyperlipidemia (High Blood Fats) | 0.4 | 0.4 | |
| hypersomnia | 0.1 | -0.1 | |
| hypertension (High Blood Pressure | 3 | 4 | -0.33 |
| Hypothyroidism | 0.4 | 0.7 | -0.75 |
| Hypoxia | 2 | 0.6 | 2.33 |
| IgA nephropathy (IgAN) | 1.3 | 4.2 | -2.23 |
| Inflammatory Bowel Disease | 5.2 | 6.7 | -0.29 |
| Insomnia | 0.7 | 2.8 | -3 |
| Intelligence | 1.4 | 0.6 | 1.33 |
| Intracranial aneurysms | 1.2 | 0.3 | 3 |
| Irritable Bowel Syndrome | 4.7 | 5.1 | -0.09 |
| ischemic stroke | 1.6 | 1.1 | 0.45 |
| Liver Cirrhosis | 4.1 | 3.2 | 0.28 |
| Long COVID | 5.7 | 5 | 0.14 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 0.6 | 1 | -0.67 |
| Mast Cell Issues / mastitis | 0.6 | -0.6 | |
| ME/CFS with IBS | 0.6 | 1.1 | -0.83 |
| ME/CFS without IBS | 1 | 0.9 | 0.11 |
| Menopause | 0.6 | 0.9 | -0.5 |
| Metabolic Syndrome | 4.8 | 5.3 | -0.1 |
| Mood Disorders | 8.2 | 5.9 | 0.39 |
| multiple chemical sensitivity [MCS] | 0.4 | 0.1 | 3 |
| Multiple Sclerosis | 3.7 | 5.9 | -0.59 |
| Multiple system atrophy (MSA) | 1 | 0.4 | 1.5 |
| myasthenia gravis | 0.7 | -0.7 | |
| neuropathic pain | 0.3 | 2.6 | -7.67 |
| Neuropathy (all types) | 0.8 | 1.6 | -1 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.3 | 0.3 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 3.2 | 3.9 | -0.22 |
| NonCeliac Gluten Sensitivity | 1.3 | 0.3 | 3.33 |
| Obesity | 7.2 | 5.7 | 0.26 |
| obsessive-compulsive disorder | 3.9 | 3 | 0.3 |
| Osteoarthritis | 1.7 | 1 | 0.7 |
| Osteoporosis | 1.6 | 1 | 0.6 |
| pancreatic cancer | 0.3 | 0.3 | |
| Parkinson's Disease | 5.1 | 4.2 | 0.21 |
| Polycystic ovary syndrome | 5.6 | 2.5 | 1.24 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.3 | -0.5 |
| Premenstrual dysphoric disorder | 0.1 | 0.4 | -3 |
| primary biliary cholangitis | 0.8 | -0.8 | |
| Primary sclerosing cholangitis | 0.9 | 2.6 | -1.89 |
| Psoriasis | 1.6 | 4 | -1.5 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 4.4 | 2.9 | 0.52 |
| Rosacea | 0.3 | 0.7 | -1.33 |
| Schizophrenia | 4.4 | 2.9 | 0.52 |
| scoliosis | 0.3 | 0.9 | -2 |
| Sjögren syndrome | 1.5 | 1.7 | -0.13 |
| Sleep Apnea | 1 | 1.8 | -0.8 |
| Slow gastric motility / Gastroparesis | 0.6 | 0.6 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.8 | 0.8 | |
| Stress / posttraumatic stress disorder | 1.9 | 2.2 | -0.16 |
| Systemic Lupus Erythematosus | 3 | 1.6 | 0.88 |
| Tic Disorder | 1.2 | 0.6 | 1 |
| Tourette syndrome | 0.4 | 0.3 | 0.33 |
| Type 1 Diabetes | 3.6 | 2.2 | 0.64 |
| Type 2 Diabetes | 6.2 | 5.6 | 0.11 |
| Ulcerative colitis | 3.2 | 6.9 | -1.16 |
| Unhealthy Ageing | 3 | 2.6 | 0.15 |
| Vitiligo | 1.9 | 1.6 | 0.19 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
